ABOUT US

A MIDAS CENTER OF EXCELLENCE

CIDID proposes an innovative, multi-disciplinary research program at the cutting edge of mathematical modeling, statistical inference methods, and computation to harvest information from a wide variety of high-quality datasets in infectious disease.

The Models of Infectious Disease Agents (MIDAS) is a NIH funded collaborative network aimed at mobilizing a highly synergystic and interdisciplinary effort between mathematical epidemiologists, statisticians, computational modelers, ecologists, and computer scientists. The advantage of our consortium is that it includes world-class leading experts in epidemic and population modeling, statistical inference, network analysis, immunization strategies, and computational modeling, that are critical for the ambitious program of the Center. 

 
“Infectious diseases continue to pose a real and significant threat to the health and welfare of people around the globe. With our multi-disciplinary approach of cutting-edge mathematical modeling and statistical methods, the MIDAS group will be able to provide national and international leaderships with our research, education and outreach programs, and public health policy related to infectious diseases and interventions.”
— Dr. M. Elizabeth (Betz) Halloran, CIDID Director
 

The Research

The Center revolves around 4 major scientific research projects, one software development component, and one policy studies component. View the projects here.

The research is motivated by public health problems and has novel implications for policy. Most importantly, the research projects will interact synergistically to provide multi-scale insight into the epidemiological, immunological and environmental determinants of transmission and evolution of infectious diseases, including, among others: 

  • influenza
  • dengue
  • cholera
  • polio

Understanding the immunological, epidemiological, and environmental determinants of spread and evolution of infectious diseases and the role of interventions such as vaccines will be a primary goal.